Please login to the form below

Not currently logged in

Silence Therapeutics appoints Michael Khan as chief medical adviser

Will advise on translational research for its siRNA-based therapeutics

UK-based biotech Silence Therapeutics has appointed Dr Michael Khan as the company's chief medical adviser.

Dr Khan is an associate professor of medicine at the University of Warwick and a consultant physician at University Hospitals.

In his role as adviser, he will help Silence develop translational clinical research involving its siRNA-based therapeutics for the treatment of orphan diseases, and those conditions with current unmet medical need.

“I believe that Silence Therapeutics core technologies are uniquely positioned to fulfil these needs,” said Dr Khan.

Dr Khan's previous roles include head of molecular medicine at Warwick University, where he helped develop various projects in cell and molecular biology.

His work has covered cancer and diabetes, and he has written several books on the subjects. He also teaches postgraduates and undergraduates in medicine and biological sciences in these areas.

In addition, Dr Khan is a fellow of the Royal College of Physicians of London and a member of the Association of Physicians, HEART-UK and Diabetes UK.

“Michael's medical, clinical and regulatory experience will be invaluable as we look to commercialise our prospects,” said Klaus Giese, chief scientific officer of Silence.

20th September 2012

From: Research



Featured jobs

Subscribe to our email news alerts


Add my company

BASTARD . LONDON collaborates with you to amplify brand ideas into a visual brand language that resonates and engages with...

Latest intelligence

How to get rep buy-in for multi-channel
How do you manage a team who may be resistant to change?...
Blog: Digital therapeutics: within our reach?
Digital therapeutics is a hot topic right now. By using digital technology to manage, treat or even prevent chronic conditions, digital therapeutics is promising to revolutionise healthcare. But is this...
figure 1
The valuable brand
Creating value beyond the pill is both possible and increasingly necessary...